Sugi Predict

Sugi Predict / Compounds / SCHEMBL3154615

SCHEMBL3154615

SCHEMBL3154615

CC(C)(C)OC(=O)NCCCN1C(=O)C=CC1=O

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.51
▸ AKT1 P31749 2/20 0.51
▸ MEN1 O00255 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ DRD2 P14416 7/20 0.47
▸ MAOA P21397 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ FAAH O00519 1/20 0.44
▸ MGLL Q99685 1/20 0.44
▸ CA12 O43570 3/20 0.44
▸ CA1 P00915 3/20 0.44
▸ CA2 P00918 3/20 0.44
▸ CA9 Q16790 3/20 0.44
▸ HSP90AA1 P07900 1/20 0.43
▸ TLR9 Q9NR96 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1449045 0.95 TDP1 (0.54) TDP1AKT1MEN1GAAKMT2A
SCHEMBL7801592 0.94 TDP1 (0.56) TDP1AKT1MEN1GAAKMT2A
SCHEMBL17738032 0.94 TDP1 (0.56) TDP1AKT1MEN1GAAKMT2A
SCHEMBL28508194 0.94 TDP1 (0.56) TDP1AKT1MEN1GAAKMT2A
SCHEMBL998261 0.91 AKT1 (0.59) TDP1AKT1MEN1GAAKMT2A
SCHEMBL15607620 0.88 AKT1 (0.47) TDP1AKT1MEN1GAAKMT2A
SCHEMBL22100919 0.86 CA1 (0.51) TDP1AKT1MEN1GAAKMT2A
SCHEMBL30269019 0.85 PTGS1 (0.48) TDP1AKT1DRD2FAAHMGLL
SCHEMBL17742314 0.84 AKT1 (0.44) TDP1AKT1MEN1GAAKMT2A
SCHEMBL25936947 0.84 AKT1 (0.44) TDP1AKT1MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 — — US disclosed
EP-4626489-A1 PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF Novartis AG (CH) 2025-10-08 — — EP disclosed
WO-2024116053-A1 PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF NOVARTIS AG (CH) 2024-06-06 — — WO disclosed
US-20220054658-A1 CONJUGATES TRANSFECTION HOLDINGS LIMITED (NZ) 2022-02-24 — — US disclosed
CN-113474007-A Conjugates 特兰斯丰特控股有限公司 2021-10-01 — — CN disclosed
US-20210132067-A1 ANTIGEN-COUPLED IMMUNOREAGENTS CELL IDX, INC. (US) 2021-05-06 — — US disclosed
US-20210032285-A1 METHODS, COMPOSITIONS, AND KITS FOR TRAPPING MODIFIED BIOMOLECULES LEICA BIOSYSTEMS NEWCASTLE LTD. (GB) 2021-02-04 — — US disclosed
WO-2020127602-A1 CONJUGATES TRANSFECTION HOLDINGS LIMITED (NZ) 2020-06-25 — — WO disclosed
US-20190233876-A1 ANTIGEN-COUPLED HYBRIDIZATION REAGENTS CELL IDX, INC. (US) 2019-08-01 — — US disclosed
US-20190125888-A1 TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF TVA (ABC), LLC 2019-05-02 — — US disclosed
WO-2016073833-A1 HIGH-AFFINITY IMMUNOPOLYMERS CELL IDX, INC. (US) 2016-05-12 — — WO disclosed
US-20140273009-A1 COMPOSITIONS AND METHODS FOR PERFORMING ASSAYS PALO ALTO RESEARCH CENTER INCORPORATED (US) 2014-09-18 — — US disclosed
US-20140273009-A1 COMPOSITIONS AND METHODS FOR PERFORMING ASSAYS PALO ALTO RESEARCH CENTER INCORPORATED (US) 2014-09-18 — — US disclosed
EP-1520176-B1 REAGENTS AND A METHOD FOR SATURATION LABELLING OF PROTEINS GE HEALTHCARE UK LTD (GB) 2010-03-10 — — EP disclosed
US-7511155-B2 Reagents and a method for saturation labelling of proteins GE HEALTHCARE UK LIMITED (GB) 2009-03-31 — — US disclosed
CN-1307263-C Fluorescent dye, method and kit for saturation labeling of proteins AMOSEN BIOLOG SCIENCE BRITISH (GB) 2007-03-28 — — CN disclosed
US-20050233462-A1 Reagents and a method for saturation labelling of proteins GLOBAL LIFE SCIENCES SOLUTIONS GERMANY GMBH (DE) 2005-10-20 — — US disclosed
CN-1650168-A Reagents and methods for saturation labelling of proteins AMOSEN BIOLOG SCIENCE BRITISH (GB) 2005-08-03 — — CN disclosed
EP-1520176-A1 REAGENTS AND A METHOD FOR SATURATION LABELLING OF PROTEINS Amersham Biosciences UK Limited (GB) 2005-04-06 — — EP disclosed
WO-2004005933-A1 REAGENTS AND A METHOD FOR SATURATION LABELLING OF PROTEINS AMERSHAM BIOSCIENCES UK LIMITED (GB) 2004-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233462-A1 Reagents and a method for saturation labelling of proteins SET, IK, MRPS22 TDP1 4738/4885AKT1 3116/4885MEN1 4059/4885
US-20190125888-A1 TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF SSTR4, SSTR5, SSTR1 TDP1 3491/4885AKT1 2374/4885MEN1 250/4885
US-20190233876-A1 ANTIGEN-COUPLED HYBRIDIZATION REAGENTS CD2BP2, HLA-C, MICA TDP1 654/4885AKT1 4002/4885MEN1 2282/4885
US-20210132067-A1 ANTIGEN-COUPLED IMMUNOREAGENTS LY96, CD2, PTPRCAP TDP1 2911/4885AKT1 3754/4885MEN1 2717/4885
US-20220054658-A1 CONJUGATES RTN3, RER1, HRH4 TDP1 1581/4885AKT1 4059/4885MEN1 2490/4885
US-20210032285-A1 METHODS, COMPOSITIONS, AND KITS FOR TRAPPING MODIFIED BIOMOLECULES PTMS, MB, RNGTT TDP1 891/4885AKT1 3591/4885MEN1 2274/4885
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A TDP1 3545/4885AKT1 2046/4885MEN1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.